Other names: Post-Transplant Cytomegalovirus (CMV) Infection/Disease

Cytomegalovirus (CMV) is a beta herpesvirus that is typically latent and asymptomatic in the body, but may reactivate during periods of immunosuppression.

People who have organ transplants (including solid organ, bone marrow, or stem cell transplant) are more likely to get an active CMV infection due to immunosuppressant therapy.

Symptoms of an active CMV infection may include fever, chills, fatigue, muscle aches, and swollen lymph nodes. If the infection progresses, it can lead to serious disease which can result in loss of the transplanted organ and failure of the graft.

Patients who are at high risk of post-transplant CMV infection can take antiviral medicines such as ganciclovir and valganciclovir as preventive therapy.

Livtencity (maribavir) is the first medicine approved specifically for the treatment of post-transplant CMV infection/disease. Livtencity is indicated for the treatment of post-transplant CMV infection/disease that has not responded to treatment with ganciclovir, valganciclovir, cidofovir or foscarnet.

Drugs used to treat CMV Infection in Transplant Patients